Related Experiment Videos
[Therapeutic perspectives of severe infectious states]
G Offenstadt1, B Guidet, V Barakett
1Service de réanimation polyvalente, hôpital Saint-Antoine, Paris.
Abstract:
Mortality from sepsis is still unacceptably high which justifies a new therapeutic approach complementary of antibiotics and symptomatic treatment. Recent advances in the understanding of sepsis and septic shock opened new fields of therapeutic intervention. Nevertheless, there are so many potential targets that is hard to make a choice for evaluation of these new agents: anti-endotoxin (monoclonal antibodies, lipid A analogs, BPI), anticytokines (monoclonal antibodies, soluble receptors, IL-1 receptor antagonist), anti-inflammatory agents (non-steroidal anti-inflammatory agents, anti-PAF, reactive oxygen radicals scavengers...), extracorporeal removal of toxic molecules, inhibition of the adhesion of polymorphonuclear leucocytes on endothelial surface, optimisation of general and regional circulation. The use of these new and often costly drugs must rely on multicenter randomized clinical trials since extrapolation to the human of experimental data gathered in animal studies are hazardous.
Insights
High sepsis mortality necessitates novel therapies beyond antibiotics. Evaluating diverse targets like anti-endotoxins and anti-cytokines requires rigorous multicenter trials due to unreliable animal data.
Area of Science:
- Critical care medicine
- Immunology
- Pharmacology
Context:
- Sepsis and septic shock continue to cause unacceptably high mortality rates.
- Current treatments primarily rely on antibiotics and symptomatic management.
- Advances in understanding sepsis pathophysiology reveal numerous potential therapeutic targets.
Purpose:
- To review emerging therapeutic strategies for sepsis that complement existing treatments.
- To discuss the challenges in selecting and evaluating novel sepsis drug candidates.
- To emphasize the necessity of robust clinical trials for validating new sepsis therapies.
Summary:
- Numerous novel therapeutic targets for sepsis have been identified, including anti-endotoxin agents (e.g., monoclonal antibodies, lipid A analogs, BPI), anticytokine therapies (e.g., monoclonal antibodies, soluble receptors, IL-1 receptor antagonist), and anti-inflammatory drugs.
- Other potential interventions include extracorporeal removal of toxic molecules, inhibiting leukocyte-endothelial adhesion, and optimizing circulation.
- The selection and evaluation of these new agents are complex due to the multitude of targets.
Impact:
- Highlights the urgent need for innovative sepsis treatments to reduce mortality.
- Underscores the critical importance of well-designed, multicenter randomized clinical trials for validating new sepsis therapies.
- Warns against the uncritical extrapolation of animal study data to human sepsis treatment.